Is Eli Lilly Stock a Buy?

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the stock up more than 1,300% over the past decade.Given its strong performance, investors may be wondering if the stock is still a buy. Let's take a closer look to help decide.While Eli Lilly has a portfolio of drugs that help address several health issues, it's the company's GLP-1 drugs that are its top sellers. Its first GLP-1 drug called Byetta, developed in conjunction with (now Bristol Myers Squibb subsidiary) Amylin Pharmaceuticals, was approved back in 2005 to help better control blood sugar levels in patients with type 2 diabetes. The two partners would later split, with Amylin paying Eli Lilly for its exenatide portfolio, including Byetta, in 2011.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool